PNC Financial Services Group Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 393,801 shares of the biopharmaceutical company's stock after buying an additional 3,626 shares during the period. PNC Financial Services Group Inc.'s holdings in Gilead Sciences were worth $36,375,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Machina Capital S.A.S. boosted its holdings in shares of Gilead Sciences by 13.6% in the 4th quarter. Machina Capital S.A.S. now owns 17,310 shares of the biopharmaceutical company's stock worth $1,599,000 after purchasing an additional 2,071 shares during the period. Aviance Capital Partners LLC boosted its stake in Gilead Sciences by 12.3% during the fourth quarter. Aviance Capital Partners LLC now owns 20,902 shares of the biopharmaceutical company's stock worth $1,931,000 after buying an additional 2,286 shares during the period. Destination Wealth Management bought a new position in Gilead Sciences during the fourth quarter valued at $362,000. Ashton Thomas Private Wealth LLC raised its stake in shares of Gilead Sciences by 2.2% in the fourth quarter. Ashton Thomas Private Wealth LLC now owns 44,217 shares of the biopharmaceutical company's stock valued at $4,084,000 after acquiring an additional 932 shares during the period. Finally, Callan Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $2,825,000. 83.67% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on GILD shares. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Oppenheimer upped their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research report on Tuesday, March 4th. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Finally, Citigroup initiated coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.52.
View Our Latest Stock Report on GILD
Insider Buying and Selling at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 over the last ninety days. Corporate insiders own 0.16% of the company's stock.
Gilead Sciences Trading Down 1.6 %
Shares of NASDAQ GILD traded down $1.91 during trading on Tuesday, reaching $115.30. The stock had a trading volume of 6,924,730 shares, compared to its average volume of 8,147,783. The business's 50-day moving average price is $100.12 and its 200-day moving average price is $91.91. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $143.59 billion, a P/E ratio of 311.66, a PEG ratio of 0.71 and a beta of 0.21.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.74%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 854.05%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
